Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more
Swissmedic-Compliant AAV Vector Manufacturing for ATMPs
EXECUTIVE SUMMARY
Swissmedic-Compliant AAV Vector Manufacturing for ATMPs
CELL & GENE | RNA | BIOLOGICS
This overview details the manufacturing framework for Adeno-Associated Virus (AAV) vectors intended for clinical evaluation in Switzerland, focusing on compliance with Swissmedic guidelines for Advanced Therapy Medicinal Products (ATMPs). It covers the Chemistry, Manufacturing, and Controls (CMC) data required for a successful Investigational Medicinal Product Dossier (IMPD) submission. The content addresses process development strategies, analytical characterization, and the definition of a manufacturing process to ensure vector quality, consistency, and purity, aligning with European regulatory expectations.
What specific CMC documentation does Swissmedic require for AAV vector ATMP manufacturing in an IMPD submission?
Swissmedic, in alignment with EMA guidelines, requires a comprehensive CMC data package for AAV vectors. This includes detailed descriptions of the manufacturing process (upstream and downstream), characterization of starting materials, a robust analytical strategy for identity, purity, and potency, and stability data. Emphasis is placed on demonstrating process consistency and control over quality attributes (CQAs) like vector genome titer, percentage of full capsids, and impurity profiles.
How does Franklin Biolabs ensure AAV production scales from preclinical research to GxP-compliant manufacturing suitable for European approvals?
Our approach is built on process continuity. The scientific team that develops the initial research-grade vector and executes preclinical programs remains engaged through the scale-up and tech transfer phases. We utilize scalable suspension and adherent platforms, from 2L to 500L+, ensuring the process established for IND-enabling toxicology studies is directly translatable to the GxP environment required for IMPD submissions.
Can you support the development of potency assays for novel AAV serotypes targeting rare diseases?
Yes. We specialize in developing and qualifying custom, gene-of-interest-specific assays, including cell-based potency assays. For novel engineered capsids or transgenes targeting indications without established biomarkers, our analytics team designs phase-appropriate assays that provide a meaningful measure of the vector’s biological activity, a requirement for regulatory submissions to agencies like Swissmedic.
A Framework for European Regulatory CMC.
Navigating the regulatory pathway for Advanced Therapy Medicinal Products (ATMPs) in Switzerland requires a manufacturing strategy that anticipates Swissmedic’s rigorous expectations from the earliest stages. A successful Investigational Medicinal Product Dossier (IMPD) is built upon a deliberate, data-driven process development program designed to produce a consistent and well-characterized AAV vector.
The core principle of gene transfer, established through foundational work on integrating genetic material into host cells (PMID: 41109216), underscores the need for impeccable vector integrity. Any variability in the manufacturing process can directly affect the quality of the final product, influencing both its intended biological function and its potential for adverse events.
A Manufacturing Process Aligned with Regulatory Scrutiny
For Swissmedic and other European authorities, demonstrating control over the manufacturing process is a primary objective. This involves a deep understanding of how process parameters affect the vector’s quality attributes.
-
Upstream Process Control: We focus on optimizing transfection parameters and media selection in scalable suspension bioreactors (up to 500L+) to maximize vector yield while maintaining batch-to-batch consistency.
-
Downstream Purification: Platform-based or client-specific purification methods are employed to effectively remove process-related impurities, such as host cell proteins and DNA, and to enrich for functional, full capsids.
-
Analytical Characterization: A comprehensive suite of platform assays provides data on vector titer, purity, aggregation, and the ratio of full to empty capsids. This analytical backbone supports the CMC section of an IMPD.
The transition from a university core to a focused commercial entity ensures this rigorous approach is maintained. As one biotech partner noted, “The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is a key scientific collaborator in our AAV-vector based gene therapy candidate development.”
Managing Immunogenicity Through Process Purity
The potential for T cell activation in response to AAV-encoded transgenes is a known biological variable that regulators scrutinize closely (PMID: 21119617). A well-controlled manufacturing process directly mitigates this risk by minimizing product-related impurities that could potentiate an immune response. Our process development is designed to reduce these risks, ensuring the final vector formulation is as pure as analytically feasible. Optimizing these processes is key to managing program timelines and costs.
The track record of our scientific leadership, which includes a 100% successful IND rate since 2019, was established on this foundation of regulatory and scientific diligence prior to the formal launch of Franklin Biolabs in 2024. This experience, now operating within a >100,000 sq ft facility, directly informs the manufacturing strategies we design for sponsors targeting European clinical trials, helping to achieve an 18-24 month timeline to IND or IMPD.
For a complete overview of our production capabilities, please see our parent hub page on Large-Scale AAV Manufacturing and Process Development.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.